Home › Compare › FOSUY vs ABBV
FOSUY yields 0.54% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, FOSUY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of FOSUY + ABBV for your $10,000?
Fosun International Limited operates in health, happiness, wealth, and intelligent manufacturing sectors in Mainland China, Portugal, and internationally. It operates in five segments: Health, Happiness, Insurance, Asset Management, and Intelligent Manufacturing. The Health segment engages in the research, development, manufacture, sale, and trading of pharmaceutical, biopharmaceutical, and health products; and provision of medical and health management services. The Happiness segment operates and invests in tourism and leisure, fashion consumer, and lifestyle industries. The Insurance segment operates and invests in the insurance markets. The Asset Management segment engages in the asset management and market investments activities. The Intelligent Manufacturing segment operates and invests in the intelligent manufacturing business; and produces iron and steel ore. It is also involved in the capital investment and management, property development, retail, and reinsurance business; manufacture and sale of iron and steel products; provision of banking and financial, and medical consultation services, as well as digital solutions. The company was founded in 1992 and is based in Shanghai, China. Fosun International Limited is a subsidiary of Fosun Holdings Limited.
Full FOSUY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.